The Global Neuroendocrine
Tumor Treatment Market, by Treatment Type (Somatostatin Analogues (SSAs)
(Octreotide, Lanreotide, and Others), Targeted Therapy, Chemotherapy, and
Others), by Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, and
Other NET), by End User (Hospitals, Oncology Centers, and Others), and by
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa), is estimated to be valued at US$ 1,448.1 million in 2019 and is
expected to exhibit a CAGR of 10.6% during the forecast period (2019-2027), as
highlighted in a new report published by Coherent Market Insights.
Several key players in the market
are engaged in conducting clinical trial studies, in order to study the safety
and efficiency of already existing therapies in the treatment of neuroendocrine
tumors. For instance, on July 3, 2019, Ipsen initiated the clinical trial to
study the effectiveness of Lanreotide 120 mg to estimate the progression-free
survival (PFS) rate in subjects with locally advanced or metastatic pancreatic
neuroendocrine tumor (PanNET) in routine clinical practice. Moreover, on
November 28, 2018, Advanced Accelerator Applications initiated the clinical
trial to study the long-term safety of LUTATHERA in unresectable or metastatic,
well-differentiated, somatostatin receptor positive gastroenteropancreatic
neuroendocrine tumor.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/129
Browse 35 Market Data Tables and
32 Figures spread through 175 Pages and in-depth TOC on Global Neuroendocrine
Tumor Treatment Market, by Treatment Type (Somatostatin Analogues (SSAs) (Octreotide,
Lanreotide, and Others), Targeted Therapy, Chemotherapy, and Others), by
Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, and Others NET), by
End User (Hospitals, Oncology Centers, and Others), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global
Forecast to 2027'
Furthermore, increasing
investments by the research institutes for research studies focusing on the
development of the novel therapies for the treatment of neuroendocrine tumors
(NETs) is expected to drive the market growth. For instance, in February 2019,
the Neuroendocrine Tumor Research Foundation (NETRF) announced grant (funding)
of US$ 2.5 million to eight new cancer research centers. With this funding,
NETRF is expected to expand its clinical development portfolio in order to
develop novel treatment options for treating lung neuroendocrine tumors (NETs).
Currently, there is no standard
treatment for pancreatic neuroendocrine tumor. However, two U.S. FDA approved
targeted therapy drugs such as Afinitor and Sutent are available in the market
for the treatment of advanced pancreatic neuroendocrine tumors and are
beneficial for some patients according to the type and severity of the
indication.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/neuroendocrine-tumors-treatment-market-129
Key Takeaways of the Global
Neuroendocrine Tumor Treatment Market:
The global neuroendocrine tumor
treatment market is expected to exhibit a CAGR of 10.6% during the forecast
period (2019-2027), owing to development and launches of product and generics
in the market. For instance, in December 2019, Par Pharmaceutical (Par), one of
the operating company of Endo International plc, received the U.S. FDA approval
to launch generic Afinitor (everolimus) 2.5 mg, 5 mg, and 7 mg tablets. The
drug is indicated for the treatment of gastrointestinal neuroendocrine tumor
(NET).
Furthermore, increasing
regulatory approvals of neuroendocrine tumor treatment is expected to drive the
market growth over the forecast period. For instance, in November 2019, U.S.
Food and Drug Administration (“FDA”) granted the Orphan Drug Designation (ODD)
to Surufatinib for the treatment of pancreatic neuroendocrine tumors. The drug
is developed by Hutchison China MediTech Limited.
Major players operating in the
global neuroendocrine tumor treatment market include Pfizer Inc, Novartis AG,
Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics
Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals
Inc., and Exelixis, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/129
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
